Copyright
©2014 Baishideng Publishing Group Inc. All rights reserved.
World J Gastroenterol. Jun 28, 2014; 20(24): 7675-7685
Published online Jun 28, 2014. doi: 10.3748/wjg.v20.i24.7675
Published online Jun 28, 2014. doi: 10.3748/wjg.v20.i24.7675
Hepatitis B virus reactivation in patients with hepatocellular carcinoma undergoing anti-cancer therapy
Jeong Won Jang, Division of Hepatology, Department of Internal Medicine, College of Medicine, The Catholic University of Korea, Seoul 137-701, South Korea
Author contributions: Jang JW solely designed and wrote the paper.
Correspondence to: Jeong Won Jang, MD, PhD, Associate Professor, Division of Hepatology, Department of Internal Medicine, College of Medicine, The Catholic University of Korea, #222 Banpo-daero, Seocho-gu, Seoul 137-701, South Korea. garden@catholic.ac.kr
Telephone: +82-2-22586015 Fax: +82-2-34814028
Received: November 1, 2013
Revised: January 22, 2014
Accepted: March 12, 2014
Published online: June 28, 2014
Revised: January 22, 2014
Accepted: March 12, 2014
Published online: June 28, 2014
Core Tip
Core tip: Hepatitis B virus (HBV) reactivation is a serious hepatic morbidity during anti-cancer therapy. The principal concern relating to reactivation is that a substantial proportion of patients with reactivation suffer from liver dysfunction, which often leads to disruption of planned, potentially life-prolonging treatments, adversely affecting the patients’ final outcome. Given the tumors and underlying cirrhosis, awareness of the management of reactivation is crucial for patients with hepatocellular carcinoma (HCC). This topic provides a summary of the literature and discusses clinical issues of HBV reactivation in HCC patients that are distinct from those in other cancer patients.